1:"$Sreact.fragment"
2:I[69243,["6874","static/chunks/6874-414075bb21e16c80.js","177","static/chunks/177-73e6fc963c87a461.js","1041","static/chunks/1041-a9b744dc93dcfcac.js","6881","static/chunks/6881-dac6bebcd7aca514.js","6992","static/chunks/6992-3dc126a235cd30c1.js","3281","static/chunks/3281-6a139c23528a1d75.js","5534","static/chunks/5534-13bd0254acbf1c0b.js","462","static/chunks/462-a92563b1cf808741.js","962","static/chunks/962-59e8700c5c690d48.js","863","static/chunks/863-9e21d85d6fff040f.js","7177","static/chunks/app/layout-63313e76c9b7ff4d.js"],""]
3:"$Sreact.suspense"
4:I[33049,["6874","static/chunks/6874-414075bb21e16c80.js","177","static/chunks/177-73e6fc963c87a461.js","1041","static/chunks/1041-a9b744dc93dcfcac.js","6881","static/chunks/6881-dac6bebcd7aca514.js","6992","static/chunks/6992-3dc126a235cd30c1.js","3281","static/chunks/3281-6a139c23528a1d75.js","5534","static/chunks/5534-13bd0254acbf1c0b.js","462","static/chunks/462-a92563b1cf808741.js","962","static/chunks/962-59e8700c5c690d48.js","863","static/chunks/863-9e21d85d6fff040f.js","7177","static/chunks/app/layout-63313e76c9b7ff4d.js"],"default"]
5:I[89157,["6874","static/chunks/6874-414075bb21e16c80.js","177","static/chunks/177-73e6fc963c87a461.js","1041","static/chunks/1041-a9b744dc93dcfcac.js","6881","static/chunks/6881-dac6bebcd7aca514.js","6992","static/chunks/6992-3dc126a235cd30c1.js","3281","static/chunks/3281-6a139c23528a1d75.js","5534","static/chunks/5534-13bd0254acbf1c0b.js","462","static/chunks/462-a92563b1cf808741.js","962","static/chunks/962-59e8700c5c690d48.js","863","static/chunks/863-9e21d85d6fff040f.js","7177","static/chunks/app/layout-63313e76c9b7ff4d.js"],"SessionProvider"]
6:I[1967,["6874","static/chunks/6874-414075bb21e16c80.js","177","static/chunks/177-73e6fc963c87a461.js","1041","static/chunks/1041-a9b744dc93dcfcac.js","6881","static/chunks/6881-dac6bebcd7aca514.js","6992","static/chunks/6992-3dc126a235cd30c1.js","3281","static/chunks/3281-6a139c23528a1d75.js","5534","static/chunks/5534-13bd0254acbf1c0b.js","462","static/chunks/462-a92563b1cf808741.js","962","static/chunks/962-59e8700c5c690d48.js","863","static/chunks/863-9e21d85d6fff040f.js","7177","static/chunks/app/layout-63313e76c9b7ff4d.js"],"default"]
7:I[87555,[],""]
8:I[31295,[],""]
d:I[28393,[],""]
:HL["/_next/static/media/26d0ba92e140f0dc-s.p.woff2","font",{"crossOrigin":"","type":"font/woff2"}]
:HL["/_next/static/media/6e8c7cb283336a9d-s.p.woff2","font",{"crossOrigin":"","type":"font/woff2"}]
:HL["/_next/static/media/bb3ef058b751a6ad-s.p.woff2","font",{"crossOrigin":"","type":"font/woff2"}]
:HL["/_next/static/css/e2fad1e045839e06.css","style"]
:HL["/_next/static/css/e897625aa354bef8.css","style"]
0:{"P":null,"b":"mMzt3wolvurVWYx1gtrcI","p":"","c":["","company","axogen-inc-axgn"],"i":false,"f":[[["",{"children":["company",{"children":[["id","axogen-inc-axgn","d"],{"children":["__PAGE__",{}]}]}]},"$undefined","$undefined",true],["",["$","$1","c",{"children":[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/e2fad1e045839e06.css","precedence":"next","crossOrigin":"$undefined","nonce":"$undefined"}],["$","link","1",{"rel":"stylesheet","href":"/_next/static/css/e897625aa354bef8.css","precedence":"next","crossOrigin":"$undefined","nonce":"$undefined"}]],["$","html",null,{"lang":"en","className":"__variable_3f4a4b __variable_8e3771 __variable_4dc837","children":[["$","head",null,{"children":["$","link",null,{"rel":"preconnect","href":"https://api.10xinsights.com","crossOrigin":"anonymous"}]}],["$","body",null,{"className":"__className_3f4a4b","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https://10xinsights.com/#org\",\"name\":\"10xInsights\",\"legalName\":\"Datanapis, LLC\",\"url\":\"https://10xinsights.com\",\"logo\":\"https://10xinsights.com/branding/10x-insights-wordmark.png\"},{\"@type\":\"WebSite\",\"@id\":\"https://10xinsights.com/#site\",\"name\":\"10xInsights\",\"url\":\"https://10xinsights.com\",\"publisher\":{\"@id\":\"https://10xinsights.com/#org\"},\"potentialAction\":{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https://10xinsights.com/?q={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}}]}"}}],["$","$L2",null,{"id":"google-tag-manager","strategy":"afterInteractive","children":"\n  window.dataLayer = window.dataLayer || [];\n  function gtag(){dataLayer.push(arguments);}\n  gtag('consent', 'default', {\n    ad_storage: 'granted',\n    ad_user_data: 'granted',\n    ad_personalization: 'granted',\n    analytics_storage: 'granted'\n  });\n  gtag('consent', 'default', {\n    ad_storage: 'denied',\n    ad_user_data: 'denied',\n    ad_personalization: 'denied',\n    analytics_storage: 'denied',\n    region: [\"AT\",\"BE\",\"BG\",\"HR\",\"CY\",\"CZ\",\"DK\",\"EE\",\"FI\",\"FR\",\"DE\",\"GR\",\"HU\",\"IE\",\"IT\",\"LV\",\"LT\",\"LU\",\"MT\",\"NL\",\"PL\",\"PT\",\"RO\",\"SK\",\"SI\",\"ES\",\"SE\",\"IS\",\"LI\",\"NO\",\"GB\",\"CH\"],\n    wait_for_update: 500\n  });\n  gtag('set', 'url_passthrough', true);\n  gtag('set', 'ads_data_redaction', true);\n  gtag('js', new Date());\n  gtag('config', 'G-S8FJFTTDXD');\n  if (location.hostname === \"10xinsights.com\") {\n    var gaLoader = document.createElement('script');\n    gaLoader.async = true;\n    gaLoader.src = 'https://www.googletagmanager.com/gtag/js?id=G-S8FJFTTDXD';\n    document.head.appendChild(gaLoader);\n  }\n"}],false,["$","$3",null,{"fallback":null,"children":["$","$L4",null,{}]}],["$","$L5",null,{"children":["$","$L6",null,{"children":["$","$L7",null,{"parallelRouterKey":"children","error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L8",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":[[["$","title",null,{"children":"404: This page could not be found."}],["$","div",null,{"style":{"fontFamily":"system-ui,\"Segoe UI\",Roboto,Helvetica,Arial,sans-serif,\"Apple Color Emoji\",\"Segoe UI Emoji\"","height":"100vh","textAlign":"center","display":"flex","flexDirection":"column","alignItems":"center","justifyContent":"center"},"children":["$","div",null,{"children":[["$","style",null,{"dangerouslySetInnerHTML":{"__html":"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}"}}],["$","h1",null,{"className":"next-error-h1","style":{"display":"inline-block","margin":"0 20px 0 0","padding":"0 23px 0 0","fontSize":24,"fontWeight":500,"verticalAlign":"top","lineHeight":"49px"},"children":404}],["$","div",null,{"style":{"display":"inline-block"},"children":["$","h2",null,{"style":{"fontSize":14,"fontWeight":400,"lineHeight":"49px","margin":0},"children":"This page could not be found."}]}]]}]}]],[]],"forbidden":"$undefined","unauthorized":"$undefined"}]}]}]]}]]}]]}],{"children":["company","$L9",{"children":[["id","axogen-inc-axgn","d"],"$La",{"children":["__PAGE__","$Lb",{},null,false]},null,false]},null,false]},null,false],"$Lc",false]],"m":"$undefined","G":["$d",[]],"s":false,"S":true}
f:I[59665,[],"OutletBoundary"]
11:I[74911,[],"AsyncMetadataOutlet"]
13:I[59665,[],"ViewportBoundary"]
15:I[59665,[],"MetadataBoundary"]
9:["$","$1","c",{"children":[null,["$","$L7",null,{"parallelRouterKey":"children","error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L8",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","forbidden":"$undefined","unauthorized":"$undefined"}]]}]
a:["$","$1","c",{"children":[null,["$","$L7",null,{"parallelRouterKey":"children","error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L8",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","forbidden":"$undefined","unauthorized":"$undefined"}]]}]
b:["$","$1","c",{"children":["$Le",null,["$","$Lf",null,{"children":["$L10",["$","$L11",null,{"promise":"$@12"}]]}]]}]
c:["$","$1","h",{"children":[null,[["$","$L13",null,{"children":"$L14"}],["$","meta",null,{"name":"next-size-adjust","content":""}]],["$","$L15",null,{"children":["$","div",null,{"hidden":true,"children":["$","$3",null,{"fallback":null,"children":"$L16"}]}]}]]}]
18:I[25114,["6874","static/chunks/6874-414075bb21e16c80.js","177","static/chunks/177-73e6fc963c87a461.js","1041","static/chunks/1041-a9b744dc93dcfcac.js","6881","static/chunks/6881-dac6bebcd7aca514.js","6992","static/chunks/6992-3dc126a235cd30c1.js","3281","static/chunks/3281-6a139c23528a1d75.js","5534","static/chunks/5534-13bd0254acbf1c0b.js","4288","static/chunks/4288-d67a2b6832127cbd.js","962","static/chunks/962-59e8700c5c690d48.js","863","static/chunks/863-9e21d85d6fff040f.js","8415","static/chunks/8415-68bd4952a63d0683.js","6208","static/chunks/app/company/%5Bid%5D/page-e14fc50473b491c2.js"],"default"]
17:T948,{"@context":"https://schema.org","@graph":[{"@type":"Corporation","@id":"https://10xinsights.com/company/axogen-inc-axgn#company","name":"Axogen, Inc.","tickerSymbol":"AXGN","identifier":[{"@type":"PropertyValue","propertyID":"CIK","value":"0000805928"},{"@type":"PropertyValue","propertyID":"SIC","value":"3845"}],"address":{"@type":"PostalAddress","addressLocality":"ALACHUA","addressRegion":"FL","addressCountry":"US"},"description":"Axogen, Inc. (NASDAQ: AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company's mission centers on restoring nerve function and quality of life for patients with peripheral nerve…","mainEntityOfPage":"https://10xinsights.com/company/axogen-inc-axgn","subjectOf":{"@id":"https://10xinsights.com/company/axogen-inc-axgn#dataset"}},{"@type":"Dataset","@id":"https://10xinsights.com/company/axogen-inc-axgn#dataset","name":"Axogen, Inc. — SEC filing data","description":"Filing-sourced data for Axogen, Inc.: Fund ownership (N-PORT), Institutional ownership (13F), Revenue, Gross profit, Operating income, Net income, Operating cash flow, Capital expenditure, Total assets, Shareholders' equity, Gross margin, Operating margin, Net margin, Return on equity, Debt to equity.","url":"https://10xinsights.com/company/axogen-inc-axgn","creator":{"@id":"https://10xinsights.com/#org"},"publisher":{"@id":"https://10xinsights.com/#org"},"isAccessibleForFree":true,"about":{"@id":"https://10xinsights.com/company/axogen-inc-axgn#company"},"variableMeasured":["Fund ownership (N-PORT)","Institutional ownership (13F)","Revenue","Gross profit","Operating income","Net income","Operating cash flow","Capital expenditure","Total assets","Shareholders' equity","Gross margin","Operating margin","Net margin","Return on equity","Debt to equity"],"temporalCoverage":"2013/2025","dateModified":"2026-10-06T10:31:11.595330771Z","isBasedOn":{"@type":"CreativeWork","name":"SEC EDGAR filings","url":"https://www.sec.gov/edgar"}},{"@type":"BreadcrumbList","@id":"https://10xinsights.com/company/axogen-inc-axgn#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://10xinsights.com"},{"@type":"ListItem","position":2,"name":"Axogen, Inc.","item":"https://10xinsights.com/company/axogen-inc-axgn"}]}]}19:T9ce,Axogen, Inc. (NASDAQ: AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company's mission centers on restoring nerve function and quality of life for patients with peripheral nerve injuries through innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers.

The company's comprehensive product portfolio includes Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft with more than 17 years of clinical evidence and over 120,000 implants since launch. In December 2025, the FDA approved Avance as an acellular nerve scaffold, with commercial availability expected in early second quarter 2026. The portfolio also encompasses the Axoguard product line, including Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, and Axoguard Nerve Cap, which are manufactured from porcine extracellular matrix material. Additionally, Axogen offers Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft launched in June 2024 for tissue protection and separation during surgical healing.

Axogen operates through a vertically integrated model combining proprietary tissue processing with a direct sales force. The company operates the Axogen Processing Center, a 107,000 square foot facility in Vandalia, Ohio, for Avance Nerve Graft tissue processing and packaging. Avive+ Soft Tissue Matrix processing occurs at a licensed facility in Dayton, Ohio. The Axoguard product line is manufactured by Evergen in West Lafayette, Indiana under supply and distribution agreements.

The company addresses a total addressable market estimated at $5.6 billion across four primary categories: extremities, oral maxillofacial and head and neck, breast reconstruction neurotization, and urology. Revenue is primarily generated through U.S. distribution of its product portfolio, supplemented by sales in Canada, Germany, the United Kingdom, Spain, and several other countries. As of December 31, 2025, Axogen employed 138 direct sales professionals in the U.S., supported by independent sales agencies representing approximately eight percent of total revenue. The company maintains a robust clinical research foundation with over 350 peer-reviewed publications and the RANGER registry tracking more than 2,800 Avance Nerve Graft repairs. More information is available at www.axogeninc.com.e:[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$17"}}],["$","$L18",null,{"id":"61637966250599248168","profile":{"registrantName":"Axogen, Inc.","tickers":["AXGN"],"primaryTicker":"AXGN","sic":"3845","hq":"ALACHUA, FL","fyEnd":"--12-31","cik":"0000805928","deregisteredDate":null,"sector":{"membership":{"sector":"Health Care","asOfQ":"2026Q2","sinceQ":"2019Q4","contested":false,"runnerUpSector":null,"fundCount":1,"evidenceFundKey":"S000004450","evidenceFundSlug":"vanguard-health-care-index-fund-vht"},"sic":{"sector":"Health Care","sicCode":"3845","matchLevel":3},"resolutionNote":null},"cityOrTown":"ALACHUA","stateOrProvince":"FL","fiscalPeriodEnd":"--12-31","id":"61637966250599248168","description":"$19","inSp500":false,"displayName":"Axogen, Inc."},"children":"$L1a"}]]
1b:I[49348,["6874","static/chunks/6874-414075bb21e16c80.js","177","static/chunks/177-73e6fc963c87a461.js","1041","static/chunks/1041-a9b744dc93dcfcac.js","6881","static/chunks/6881-dac6bebcd7aca514.js","6992","static/chunks/6992-3dc126a235cd30c1.js","3281","static/chunks/3281-6a139c23528a1d75.js","5534","static/chunks/5534-13bd0254acbf1c0b.js","4288","static/chunks/4288-d67a2b6832127cbd.js","962","static/chunks/962-59e8700c5c690d48.js","863","static/chunks/863-9e21d85d6fff040f.js","8415","static/chunks/8415-68bd4952a63d0683.js","6208","static/chunks/app/company/%5Bid%5D/page-e14fc50473b491c2.js"],"default"]
1c:T9ce,Axogen, Inc. (NASDAQ: AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company's mission centers on restoring nerve function and quality of life for patients with peripheral nerve injuries through innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers.

The company's comprehensive product portfolio includes Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft with more than 17 years of clinical evidence and over 120,000 implants since launch. In December 2025, the FDA approved Avance as an acellular nerve scaffold, with commercial availability expected in early second quarter 2026. The portfolio also encompasses the Axoguard product line, including Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, and Axoguard Nerve Cap, which are manufactured from porcine extracellular matrix material. Additionally, Axogen offers Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft launched in June 2024 for tissue protection and separation during surgical healing.

Axogen operates through a vertically integrated model combining proprietary tissue processing with a direct sales force. The company operates the Axogen Processing Center, a 107,000 square foot facility in Vandalia, Ohio, for Avance Nerve Graft tissue processing and packaging. Avive+ Soft Tissue Matrix processing occurs at a licensed facility in Dayton, Ohio. The Axoguard product line is manufactured by Evergen in West Lafayette, Indiana under supply and distribution agreements.

The company addresses a total addressable market estimated at $5.6 billion across four primary categories: extremities, oral maxillofacial and head and neck, breast reconstruction neurotization, and urology. Revenue is primarily generated through U.S. distribution of its product portfolio, supplemented by sales in Canada, Germany, the United Kingdom, Spain, and several other countries. As of December 31, 2025, Axogen employed 138 direct sales professionals in the U.S., supported by independent sales agencies representing approximately eight percent of total revenue. The company maintains a robust clinical research foundation with over 350 peer-reviewed publications and the RANGER registry tracking more than 2,800 Avance Nerve Graft repairs. More information is available at www.axogeninc.com.1a:["$","$L1b",null,{"summary":{"entityInfo":{"id":"61637966250599248168","registrantName":"Axogen, Inc.","displayName":"Axogen, Inc.","tickers":"$e:1:props:profile:tickers","sic":"3845","cik":"0000805928","cityOrTown":"ALACHUA","stateOrProvince":"FL","fiscalPeriodEnd":"--12-31","inSp500":false,"deregisteredDate":null,"sector":"$e:1:props:profile:sector"},"description":"$1c","index":["REVENUE","GROSS_PROFIT","OPERATING_INCOME_LOSS","NET_INCOME_LOSS","NET_CASH_OPERATING","CAPITAL_EXPENDITURE","ASSETS","SHAREHOLDERS_EQUITY","GROSS_MARGIN","OPERATING_MARGIN","NET_MARGIN","ROE","DEBT_EQUITY_RATIO","WEIGHTED_AVERAGE_SHARES_DILUTED"],"data":[[10.947361,16.817403,27.331092,41.107538,60.426395,83.937,106.712,112.3,127.358,138.584,159.012,187.338,225.208,251.17399999999998],[8.507543,13.37522,22.482696,34.640288,51.11481,71.014,89.363,90.719,104.427,114.437,127.874,141.977,167.353,187.26500000000001],[-9.592205,-9.80079,-9.26671,-8.129862,-7.951286,-20.5,-31.406,-23.182,-25.416,-29.707,-21.462,-3.287,-7.849,-12.847999999999999],[-14.556885,-17.710476,-13.356425,-14.411144,-10.445462,-22.397,-29.135,-23.786,-26.985,-28.948,-21.716,-9.964,-15.703,-33.547999999999995],[-10.444758,-10.451059,-13.051819,-11.204442,-9.237599,-17.862,-19.872,-9.626,-13.405,-16.066,-5.716,4.535,0.812,15.046999999999999],[0.178776,0.542045,0.408782,0.963787,1.105212,6.282,4.664,21.905,27.811,20.078,13.872,3.101,3.745,6.449],[27.68427,16.400789,37.546053,46.360478,58.874698,160.173,154.643,201.381,208.024,195.387,196.827,203.728,221.687,304.863],[0.136633,-11.24568,8.195591,14.921149,25.182035,146.982,132.153,123.149,112.55,100.999,95.665,103.907,128.847,256.257],[0.7771318585365002,0.7953201811242795,0.8226051121557821,0.8426748398310792,0.8459020267550298,0.8460392913732918,0.8374222205562636,0.8078272484416741,0.8199484916534494,0.8257591063903481,0.8041783010087289,0.7578654624262029,0.7431041526055914,0.7455588556140366],[-0.8762116276242282,-0.5827766629603869,-0.33905377801955366,-0.19777058893675412,-0.13158630429632612,-0.24423079214172536,-0.2943061698778019,-0.20642920747996438,-0.1995634353554547,-0.21436096519078682,-0.13497094558901215,-0.017545826260555786,-0.0348522254982061,-0.05115179118857843],[-1.329716358125031,-1.0531040969881023,-0.4886897676829012,-0.3505718099682837,-0.17286257106683262,-0.26683107568771813,-0.2730245895494415,-0.21180765805877116,-0.21188303836429592,-0.20888414246954914,-0.1365683093099892,-0.05318728714943045,-0.06972665269439807,-0.13356477979408696],[-106.54003791177826,1.5748692831380584,-1.6297085835542549,-0.9658199914765278,-0.41479816861504637,-0.15237920289559265,-0.22046415896725768,-0.1931481376219052,-0.23976010661928032,-0.28661669917523935,-0.22700047039147023,-0.09589344317514702,-0.12187322948923916,-0.13091544816336723],[185.6337414826579,-2.2307034345633165,3.1172150977275463,1.6293428207170908,0.9784873621214489,0.0004286239131322203,0.025205632864936853,0.2600670732202454,0.3982318969346957,0.45259854057960974,0.4871478597188104,0.45710106152617247,0.37553842929986725,0],[13.499793,17.721742,26.07567,30.702164,33.322767,37.126999999999995,39.235,39.967,41.215,42.083125,42.878543,44.257754,46.050266,52.562976]],"columns":[{"start":"2013-01-01","end":"2013-12-31"},{"start":"2014-01-01","end":"2014-12-31"},{"start":"2015-01-01","end":"2015-12-31"},{"start":"2016-01-01","end":"2016-12-31"},{"start":"2017-01-01","end":"2017-12-31"},{"start":"2018-01-01","end":"2018-12-31"},{"start":"2019-01-01","end":"2019-12-31"},{"start":"2020-01-01","end":"2020-12-31"},{"start":"2021-01-01","end":"2021-12-31"},{"start":"2022-01-01","end":"2022-12-31"},{"start":"2023-01-01","end":"2023-12-31"},{"start":"2024-01-01","end":"2024-12-31"},{"start":"2025-01-01","end":"2025-12-31"},{"start":"2025-07-01","end":"2026-06-30"}],"columnKinds":["FY","FY","FY","FY","FY","FY","FY","FY","FY","FY","FY","FY","FY","TTM"],"currencies":["USD","USD","USD","USD","USD","USD","USD","USD","USD","USD","USD","USD","USD","USD"],"restated":[false,false,false,false,false,false,false,false,false,false,false,false,false,false],"columnSource":["AS_FILED","AS_FILED","AS_FILED","AS_FILED","AS_FILED","AS_FILED","AS_FILED","AS_FILED","AS_FILED","AS_FILED","AS_FILED","AS_FILED","AS_FILED","AS_FILED"]},"ownership":{"fundCount":228,"fundValueUsd":729304821,"pctOwnedByFunds":30.22,"sharesOutAsOf":null,"shareClasses":[{"ticker":"AXGN","titleOfClass":"Common Stock, $0.01 par value","pctOwnedByFunds":30.22,"holderFundCount":228,"sharesOutstanding":53761513,"sharesOutAsOf":"2026-07-27"}],"superinvestorCount":0,"superinvestorFilerCount":35,"reportQuarter":"2026Q2","thirteenFPeriod":"2026-06-30","topFundHolders":[{"fundKey":"S000002848","fundName":"VANGUARD TOTAL STOCK MARKET INDEX FUND","ticker":"VTI","registrantName":"VANGUARD INDEX FUNDS","valueUsd":73726122,"pctNav":0.0032084979533885598,"fundSlug":"vanguard-total-stock-market-index-fund-vti"},{"fundKey":"S000004344","fundName":"iShares Russell 2000 ETF","ticker":"IWM","registrantName":"iShares Trust","valueUsd":63455083,"pctNav":0.07647922617239428,"fundSlug":"ishares-russell-2000-etf-iwm"},{"fundKey":"S000012813","fundName":"Hood River Small-Cap Growth Fund","ticker":"HRSMX","registrantName":"Manager Directed Portfolios","valueUsd":31772207,"pctNav":0.4777378715592524,"fundSlug":"hood-river-small-cap-growth-fund-hrsmx"},{"fundKey":"S000002841","fundName":"VANGUARD EXTENDED MARKET INDEX FUND","ticker":"VXF","registrantName":"VANGUARD INDEX FUNDS","valueUsd":28163336,"pctNav":0.028826808518305342,"fundSlug":"vanguard-extended-market-index-fund-vxf"},{"fundKey":"S000002106","fundName":"T. Rowe Price New Horizons Fund, Inc.","ticker":"PRNHX","registrantName":"T. ROWE PRICE NEW HORIZONS FUND, INC.","valueUsd":27168958,"pctNav":0.18460139198918524,"fundSlug":"t-rowe-price-new-horizons-fund-inc-prnhx"}],"topSuperinvestors":[],"bondCount":null,"bondValueUsd":null,"bonds":[],"bondSummary":null,"resolutionNote":"Could not be determined for this company: bond issues."},"filings":[{"filingId":393005,"formType":"10-Q","fiscalYear":2026,"fiscalPeriod":"Q2","dateFiled":"2026-07-29","amended":false},{"filingId":387617,"formType":"10-Q","fiscalYear":2026,"fiscalPeriod":"Q1","dateFiled":"2026-04-28","amended":false},{"filingId":383309,"formType":"10-K","fiscalYear":2025,"fiscalPeriod":"FY","dateFiled":"2026-02-24","amended":false},{"filingId":371629,"formType":"10-Q","fiscalYear":2025,"fiscalPeriod":"Q3","dateFiled":"2025-10-29","amended":false},{"filingId":371630,"formType":"10-Q","fiscalYear":2025,"fiscalPeriod":"Q2","dateFiled":"2025-08-05","amended":false},{"filingId":368601,"formType":"10-Q","fiscalYear":2025,"fiscalPeriod":"Q1","dateFiled":"2025-05-08","amended":false},{"filingId":364928,"formType":"10-K","fiscalYear":2024,"fiscalPeriod":"FY","dateFiled":"2025-02-26","amended":false},{"filingId":353984,"formType":"10-Q","fiscalYear":2024,"fiscalPeriod":"Q3","dateFiled":"2024-11-07","amended":false},{"filingId":350611,"formType":"10-Q","fiscalYear":2024,"fiscalPeriod":"Q2","dateFiled":"2024-08-08","amended":false},{"filingId":339954,"formType":"10-Q","fiscalYear":2024,"fiscalPeriod":"Q1","dateFiled":"2024-05-02","amended":false}],"signInHref":"/sign-in?returnUrl=%2Fcompany%2Faxogen-inc-axgn"}]
14:[["$","meta","0",{"charSet":"utf-8"}],["$","meta","1",{"name":"viewport","content":"width=device-width, initial-scale=1"}]]
10:null
1d:I[38175,[],"IconMark"]
12:{"metadata":[["$","title","0",{"children":"Axogen, Inc. (AXGN) · 10x Insights"}],["$","meta","1",{"name":"description","content":"Axogen, Inc. (NASDAQ: AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve…"}],["$","link","2",{"rel":"canonical","href":"https://10xinsights.com/company/axogen-inc-axgn"}],["$","meta","3",{"property":"og:title","content":"Axogen, Inc. (AXGN) · 10x Insights"}],["$","meta","4",{"property":"og:description","content":"Axogen, Inc. (NASDAQ: AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve…"}],["$","meta","5",{"property":"og:url","content":"https://10xinsights.com/company/axogen-inc-axgn"}],["$","meta","6",{"property":"og:site_name","content":"10xInsights"}],["$","meta","7",{"property":"og:type","content":"website"}],["$","meta","8",{"name":"twitter:card","content":"summary"}],["$","meta","9",{"name":"twitter:title","content":"Axogen, Inc. (AXGN) · 10x Insights"}],["$","meta","10",{"name":"twitter:description","content":"Axogen, Inc. (NASDAQ: AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve…"}],["$","link","11",{"rel":"icon","href":"/icon.svg?78c58921da567733","type":"image/svg+xml","sizes":"any"}],["$","$L1d","12",{}]],"error":null,"digest":"$undefined"}
16:"$12:metadata"
